Table 5.
Apolipoprotein B and β2-glycoprotein-I (GPI) autoantibodies in systemic lupus erythematosus (SLE) patients with and without organ damage (SDI > 1)
| SDI > 1 median (IQR)* | SDI ≤ 1 median (IQR)* | P | P adjusted for age and gender | |
|---|---|---|---|---|
| Apolipoprotein B antibodies | ||||
| p45 IgM | 0·53 (0·24–1·19) | 0·72 (0·36–1·38) | 0·02 | n.s. |
| MDA-p45 IgM | 0·60 (0·28–1·22) | 0·79 (0·44–1·55) | 0·003 | n.s. |
| p45 IgG | 0·48 (0·19–0·91) | 0·50 (0·24–1·04) | n.s. | n.s. |
| MDA-p45 IgG | 0·50 (0·30–0·97) | 0·56 (0·27–1·03) | n.s. | n.s. |
| p210 IgM | 0·68 (0·44–1·02) | 0·83 (0·57–1·07) | 0·006 | n.s. |
| MDA-p210 IgM | 0·80 (0·55–1·02) | 0·89 (0·68–1·05) | n.s. | n.s. |
| p210 IgG | 0·37 (0·16–0·66) | 0·54 (0·28–0·95) | 0·001 | n.s. |
| MDA-p210 IgG | 0·61 (0·41–0·84) | 0·76 (0·56–1·05) | 0·001 | 0·005 |
| Apolipoprotein H antibodies | ||||
| β2GPI IgM | 1·9 (1·9–5·9) | 1·9 (1·9–3·1) | n.s. | n.s. |
| β2GPI IgG | 2·1 (1·9–21·5) | 1·9 (1·9–7·6) | 0·02 | 0·006 |
*
Distributions are given as median [interquartile range (IQR)].
Ig = immunoglobulin; MDA = malondialdehyde; SDI = Systemic Lupus International Collaborating Clinics damage index; n.s. = not significant.